Evidence map›Paper›PMID 38831835›Full record

ArticleHeliyon2024

DO disease stages affect oxidative stress in stable COPD?

Murat Yalcinsoy, Aysegul Beykumul, Gazi Gulbas, Ahmet Kadir Arslan, Salim Neselioglu

Abstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Murat YalcinsoyDepartment of Pulmonary Medicine, Inonu University Medical Faculty, Turgut Ozal Medical Center, Malatya, Turkey.
Aysegul BeykumulDepartment of Pulmonary Rehabilitation, Inonu University Medical Faculty, Turgut Ozal Medical Center, Malatya, Turkey.
Gazi GulbasDepartment of Pulmonary Rehabilitation, Inonu University Medical Faculty, Turgut Ozal Medical Center, Malatya, Turkey.
Ahmet Kadir ArslanDepartment of Biostatistics, Inonu University, Malatya, Turkey.
Salim NeseliogluDepartment of Biochemistry, Yıldırım Beyazıt University Medical Faculty, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Detection of oxidative stress level may lead us to understand the pathogenesis of COPD better and to search for new treatments. Oxidative stress levels have also been shown to be elevated in stable COPD patients. We aimed to investigate whether the stage of COPD affects the severity of inflammation-induced oxidative stress in patients with stable COPD. Methods: Between June 2019 and March 2020, all consecutive patients admitted to COPD-specific outpatient clinics were included. Patients were classified A, B, and E according to the GOLD guideline. Results: The median age of 98 patients (Male: 92 (93.9 %)) was 65 (min-max: 49-86). A statistically significant difference was found between the groups in FEV1, FVC, and FEV1/FVC (p < 0.001). age, and thiols (r = -0.168, p = 0.049; r = -0.184, p = 0.035) and DS (r = -0.209, p = 0.019) were found to be negatively correlated at a low level. When adjusted for age, oxidative stress parameters were similar between stages. Conclusion: No difference between stages and oxidative stress parameters according to GOLD classification in stable COPD patients. Our results may be a guide for not using anti-inflammatory therapy except for attacks.

Indexed as

COPDCOPD stagesDisulfideOxidative stressThiol

Identifiers

PMID38831835
PMCPMC11145427

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.